<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00664859</url>
  </required_header>
  <id_info>
    <org_study_id>LCP-AtorFen-2001-1X</org_study_id>
    <nct_id>NCT00664859</nct_id>
  </id_info>
  <brief_title>12-Month, Open-Label, Extension Study of LCP-AtorFen in Dyslipidemia</brief_title>
  <official_title>A 12-Month, Open-Label, Extension Study of the Safety and Efficacy of LCP-AtorFen in Subjects With Dyslipidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Veloxis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Veloxis Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current study is designed to test the long-term (12-month) safety and efficacy of
      LCP-AtorFen, a combination of atorvastatin and fenofibrate, in patients with dyslipidemia
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      POPULATION:

      Subjects with mixed dyslipidemia (non-HDL cholesterol &gt; 130 mg/dL and TG ≥ 150 mg/dL and ≤
      500 mg/dL) who completed the double-blind study (LCP-AtorFen-2001; NCT00504829), met the
      enrollment criteria (all of the inclusion criteria and none of the exclusion criteria), and
      elected to enter the open-label extension study.

      STUDY DESIGN AND DURATION:

      This is a 52-week, open-label, single-treatment arm with 8 visits (Weeks 0, 4, 8, 12, 24, 36,
      48 and 52). A maximum of approximately 200 subjects will enter this open-label safety and
      efficacy extension study from the LCP AtorFen-2001 double-blind study. All subjects enrolled
      in this study will receive open-label LCP-AtorFen combination therapy. Visit 1 of the
      extension study corresponds to the last visit of the double-blind study (Visit 6 or Week 12).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Non-HDL Cholesterol, HDL Cholesterol, TG Levels From Baseline to End of Treatment</measure>
    <time_frame>52 weeks from DB baseline and 40 weeks from OL baseline</time_frame>
    <description>Mean percent changes in non-HDL cholesterol, HDL cholesterol, TG levels from the double-blind (DB) baseline (Week 0) to end-of-treatment (Week 52), and from the open-label (OL) baseline (week 12 of DB study) to end of treatment (Week 52)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in LDL Cholesterol, VLDL, Total Cholesterol, Apo A-1, and Apo B From Baseline to End of Treatment</measure>
    <time_frame>52 weeks from DB baseline and 40 weeks from OL baseline</time_frame>
    <description>Mean percent changes in LDL cholesterol, VLDL, total cholesterol, Apo A-1, and Apo B from the double-blind (DB) baseline (Week 0) to end-of-treatment (Week 52), and from the open-label (OL) baseline (week 12) to end-of-treatment (Week 52)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>Single</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open-label LCP-AtorFen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LCP-AtorFen</intervention_name>
    <description>All subjects will be assigned to receive open-label LCP-AtorFen combination therapy for 52 weeks. Subjects will take a single oral dose of study drug in the evening without regard to meals.</description>
    <arm_group_label>Single</arm_group_label>
    <other_name>atorvastatin and fenofibrate combination therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject has successfully completed the double-blind study (LCP-AtorFen-2001;
             NCT00504829).

          2. Subject has confirmed his or her willingness to participate in this study after being
             informed of all aspects of the study by voluntarily signing and dating an informed
             consent form in accordance with Good Clinical Practice (GCP).

        Exclusion Criteria:

          1. Study drug compliance &lt;70% in the double-blind study.

          2. Any ongoing serious adverse event, or any ongoing non-serious moderate or severe
             adverse event from the double-blind study that is rated as possibly, probably or
             definitely related to study drug.

          3. Resting blood pressure &gt;/=160 mm Hg systolic and/or &gt;/=100 mm Hg diastolic.

          4. Symptoms of unexplained muscle pain, tenderness or weakness (i.e., signs indicative of
             possible myopathy), or any diagnosis of myopathy or rhabdomyolysis.

          5. Any clinically significant change in physical exam or electrocardiogram from Visit 2
             to Visit 6 of the double-blind study.

          6. Any clinically significant change from Visit 1 to Visit 6 of the double-blind study in
             medical history including, but not limited to: a diagnosis of insulin-dependent
             diabetes mellitus (DM); poorly controlled DM; poorly controlled hypertension;
             significant renal, pulmonary, hepatic, biliary, or gastrointestinal disease; cancer
             (except non-melanoma skin cancer); and epilepsy.

          7. Unwilling to abstain from medications, supplements, ingredients and herbal therapies
             that were excluded in the double-blind study and continue to be excluded in the
             open-label study.

          8. Women who are pregnant, planning to be pregnant during the study period, lactating, or
             women of childbearing potential (not surgically sterilized between menarche and
             menopause) who are not using a medically approved method of contraception.

          9. Other exclusion conditions might apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeff Geohas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radiant Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dennis McCluskey, MD</last_name>
    <role>Study Director</role>
    <affiliation>Radiant Resaerch</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Harry Geisberg, MD</last_name>
    <role>Study Director</role>
    <affiliation>Radiant Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chivers Woodruff, Jr, MD</last_name>
    <role>Study Director</role>
    <affiliation>Radiant Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Noss, MD</last_name>
    <role>Study Director</role>
    <affiliation>Radiant Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michele Reynolds, MD</last_name>
    <role>Study Director</role>
    <affiliation>Radiant Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James Zavoral, MD</last_name>
    <role>Study Director</role>
    <affiliation>Radiant Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Randall Severance, MD</last_name>
    <role>Study Director</role>
    <affiliation>Radiant Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephen Halpern, MD</last_name>
    <role>Study Director</role>
    <affiliation>Radiant Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Linda Murray, MD</last_name>
    <role>Study Director</role>
    <affiliation>Radiant Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eduardo Cuevas, MD</last_name>
    <role>Study Director</role>
    <affiliation>Radiant Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cynthia Strout, MD</last_name>
    <role>Study Director</role>
    <affiliation>Coastal Carolina Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Kipnes, MD</last_name>
    <role>Study Director</role>
    <affiliation>Diabetes and Glandular Research Center, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radiant Research, 515 N State St, Suite 2700</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>April 21, 2008</study_first_submitted>
  <study_first_submitted_qc>April 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2008</study_first_posted>
  <results_first_submitted>February 14, 2020</results_first_submitted>
  <results_first_submitted_qc>March 2, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 24, 2020</results_first_posted>
  <last_update_submitted>March 2, 2020</last_update_submitted>
  <last_update_submitted_qc>March 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LCP-AtorFen</keyword>
  <keyword>Non-HDL cholesterol</keyword>
  <keyword>Triglycerides</keyword>
  <keyword>HDL cholesterol</keyword>
  <keyword>LDL cholesterol</keyword>
  <keyword>Atorvastatin</keyword>
  <keyword>Fenofibrate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
    <mesh_term>Fenofibrate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Of the 192 subjects who completed the double-blind (DB) period, 140 rolled over into the extension study and received at least one dose of open-label (OL) study drug to form the safety population.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>LCP-AtorFen 40/100 mg</title>
          <description>Subjects randomized to LCP-AtorFen 40/100 mg/day in the DB portion of the study</description>
        </group>
        <group group_id="P2">
          <title>Atorvastatin 40 mg</title>
          <description>Subjects randomized to Atorvastatin 40 mg/day in the DB portion of the study</description>
        </group>
        <group group_id="P3">
          <title>Fenofibrate 145 mg</title>
          <description>Subjects randomized to Fenofibrate 145 mg/day in the DB portion of the study</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="45"/>
                <participants group_id="P3" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="35"/>
                <participants group_id="P3" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>DB Study (LCP-AtorFen-2001) AE</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance with protocol</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Laboratory abnormality</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>LCP-AtorFen 40/100mg</title>
          <description>Data presented by previous double-blind study assignment</description>
        </group>
        <group group_id="B2">
          <title>Atorvastatin 40 mg</title>
          <description>Data presented by previous double-blind study assignment</description>
        </group>
        <group group_id="B3">
          <title>Fenofibrate 145 mg</title>
          <description>Data presented by previous double-blind study assignment</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="51"/>
            <count group_id="B2" value="45"/>
            <count group_id="B3" value="44"/>
            <count group_id="B4" value="140"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.6" spread="10.86"/>
                    <measurement group_id="B2" value="55.6" spread="9.03"/>
                    <measurement group_id="B3" value="57.2" spread="11.23"/>
                    <measurement group_id="B4" value="55.7" spread="10.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Amer. Indian /Alaskan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black/African</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hawaiian/Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Non-HDL Cholesterol, HDL Cholesterol, TG Levels From Baseline to End of Treatment</title>
        <description>Mean percent changes in non-HDL cholesterol, HDL cholesterol, TG levels from the double-blind (DB) baseline (Week 0) to end-of-treatment (Week 52), and from the open-label (OL) baseline (week 12 of DB study) to end of treatment (Week 52)</description>
        <time_frame>52 weeks from DB baseline and 40 weeks from OL baseline</time_frame>
        <population>Modified intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>LCP-AtorFen 40/100mg</title>
            <description>Data presented by previous double-blind study assignment</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 40 mg</title>
            <description>Data presented by previous double-blind study assignment</description>
          </group>
          <group group_id="O3">
            <title>Fenofibrate 145 mg</title>
            <description>Data presented by previous double-blind study assignment</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Non-HDL Cholesterol, HDL Cholesterol, TG Levels From Baseline to End of Treatment</title>
          <description>Mean percent changes in non-HDL cholesterol, HDL cholesterol, TG levels from the double-blind (DB) baseline (Week 0) to end-of-treatment (Week 52), and from the open-label (OL) baseline (week 12 of DB study) to end of treatment (Week 52)</description>
          <population>Modified intent-to-treat population</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Non-HDL cholesterol, change from DB baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-48.2" spread="13.58"/>
                    <measurement group_id="O2" value="-43.6" spread="18.18"/>
                    <measurement group_id="O3" value="-42.0" spread="20.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-HDL cholesterol change from OL baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="22.39"/>
                    <measurement group_id="O2" value="2.8" spread="33.67"/>
                    <measurement group_id="O3" value="-29.6" spread="26.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides change from DB baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-53.1" spread="25.31"/>
                    <measurement group_id="O2" value="-51.2" spread="23.23"/>
                    <measurement group_id="O3" value="-42.1" spread="29.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides change from OL baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.4" spread="65.36"/>
                    <measurement group_id="O2" value="-19.1" spread="40.42"/>
                    <measurement group_id="O3" value="-5.2" spread="53.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL cholesterol change from DB baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.1" spread="21.7"/>
                    <measurement group_id="O2" value="16.3" spread="18.67"/>
                    <measurement group_id="O3" value="17.5" spread="20.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL cholesterol change from OL baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="16.9"/>
                    <measurement group_id="O2" value="10.1" spread="17.77"/>
                    <measurement group_id="O3" value="-2.4" spread="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in LDL Cholesterol, VLDL, Total Cholesterol, Apo A-1, and Apo B From Baseline to End of Treatment</title>
        <description>Mean percent changes in LDL cholesterol, VLDL, total cholesterol, Apo A-1, and Apo B from the double-blind (DB) baseline (Week 0) to end-of-treatment (Week 52), and from the open-label (OL) baseline (week 12) to end-of-treatment (Week 52)</description>
        <time_frame>52 weeks from DB baseline and 40 weeks from OL baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LCP-AtorFen 40/100mg</title>
            <description>Data presented by previous double-blind study assignment</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 40 mg</title>
            <description>Data presented by previous double-blind study assignment</description>
          </group>
          <group group_id="O3">
            <title>Fenofibrate 145 mg</title>
            <description>Data presented by previous double-blind study assignment</description>
          </group>
        </group_list>
        <measure>
          <title>Change in LDL Cholesterol, VLDL, Total Cholesterol, Apo A-1, and Apo B From Baseline to End of Treatment</title>
          <description>Mean percent changes in LDL cholesterol, VLDL, total cholesterol, Apo A-1, and Apo B from the double-blind (DB) baseline (Week 0) to end-of-treatment (Week 52), and from the open-label (OL) baseline (week 12) to end-of-treatment (Week 52)</description>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LDL-C change from DB baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-44.8" spread="15.92"/>
                    <measurement group_id="O2" value="-39.3" spread="20.04"/>
                    <measurement group_id="O3" value="-40.9" spread="22.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL-C change from OL baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="25.09"/>
                    <measurement group_id="O2" value="14" spread="36.29"/>
                    <measurement group_id="O3" value="-33.6" spread="24.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VLDL-C change from DB baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-53.6" spread="23.98"/>
                    <measurement group_id="O2" value="-51.1" spread="23.07"/>
                    <measurement group_id="O3" value="-42.0" spread="29.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VLDL-C change from OL baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7" spread="69.42"/>
                    <measurement group_id="O2" value="-18.7" spread="39.97"/>
                    <measurement group_id="O3" value="-5.5" spread="51.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total-C change from DB baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-36.5" spread="11.07"/>
                    <measurement group_id="O2" value="-33.8" spread="14.6"/>
                    <measurement group_id="O3" value="-32.8" spread="16.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total-C change from OL baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="12.95"/>
                    <measurement group_id="O2" value="4.6" spread="24.54"/>
                    <measurement group_id="O3" value="-24.4" spread="19.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Apo A-1 change from DB baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="13.21"/>
                    <measurement group_id="O2" value="1.0" spread="9.88"/>
                    <measurement group_id="O3" value="0.4" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Apo-A-1 change from OL baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="8.11"/>
                    <measurement group_id="O2" value="1.9" spread="13.62"/>
                    <measurement group_id="O3" value="-5.1" spread="11.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Apo B change from DB baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-42.4" spread="11.85"/>
                    <measurement group_id="O2" value="-38.9" spread="16.26"/>
                    <measurement group_id="O3" value="-36.8" spread="18.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Apo B change from OL baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="17.69"/>
                    <measurement group_id="O2" value="-1.5" spread="25.14"/>
                    <measurement group_id="O3" value="-25.5" spread="21.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>LCP-AtorFen 40/100mg</title>
          <description>Data presented by previous double-blind study assignment</description>
        </group>
        <group group_id="E2">
          <title>Atorvastatin 40 mg</title>
          <description>Data presented by previous double-blind study assignment</description>
        </group>
        <group group_id="E3">
          <title>Fenofibrate 145 mg</title>
          <description>Data presented by previous double-blind study assignment</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fracture treatment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Elevated ALT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Rectal cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The study is a multicenter collaborative investigation and the clinical trial results are to be published as a collaborative manuscript. Authorship will reflect varying levels of individual contribution to the study by the individual PI's.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director, Regulatory Affairs</name_or_title>
      <organization>Veloxis Pharmaceuticals, Inc.</organization>
      <phone>919-591-3090</phone>
      <email>bbu@veloxis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

